{"paper_id":"bbb73bca-66f5-4f3a-a75c-ea0eb6fc4720","body_text":"Leuprorelin acetate hormone therapy in the management of ovarian endometriosis: A case report\nDOI:\nhttps://doi.org/10.33024/minh.v8i5.852Keywords:\nHormone Therapy, Leuprorelin Acetate, Ovarian EndometriosisAbstract\nBackground: Endometriosis is a condition characterized by the growth of endometrial tissue outside the uterus, which can cause pelvic pain and problems in the reproductive system. Endometriosis usually occurs during reproductive age. The symptoms of endometriosis depend on the location of the endometrial cells. The main complaint that often appears is pelvic pain, so about 71-87% of cases are diagnosed due to severe chronic pain during menstruation, while only 38% are detected due to infertility problems. Proper treatment of endometriosis is necessary, as many women are often diagnosed too late, leading to suffering and decreased quality of life. One of the medical approaches used is hormone therapy.\nPurpose: To aprove Leuprorelin acetate hormone therapy in helping the treatment of Ovarian Endometriosis.\nMethod: This descriptive analytic research used a case study approach involving a 37-year-old female patient with ovarian endometriosis at the Obstetrics and Gynecology Polyclinic of Dompu General Hospital. The study followed ethical principles and obtained informed consent. Data were collected through interviews, observation, physical examinations, medical records, and diagnostic documentation, using a head-to-toe assessment format. Data analysis was conducted concurrently with data collection, comparing findings with existing theories to support discussion and intervention recommendations. The analysis was narrative and observational, aiming to interpret the patient’s condition in relation to theoretical knowledge.\nResults: Hormone therapy with Leuprorelin acetate was administered in this case at a dose of 3.75 mg per injection for three months. The results of the ultrasound examination showed a reduction in the size of the ovarian mass, and the patient's pain significantly decreased.\nConclusion: Leuprorelin acetate hormone therapy can serve as an effective alternative to surgery in managing symptoms of ovarian endometriosis.\nDownloads\nReferences\nAkbar, M. I. A., Tjokroprawiro, B. A., & Hendarto, H. (2020). Ginekologi Praktis Komprehensif (Vol. 2). Airlangga University Press.\nBuggio, L., Dridi, D., Barbara, G., Merli, C. E., Cetera, G. E., & Vercellini, P. (2022). Novel Pharmacological Therapies For The Treatment Of Endometriosis. Expert Review Of Clinical Pharmacology, 15(9), 1039-1052.\nCarsote, M., Terzea, D. C., Valea, A., & Gheorghisan-Galateanu, A. A. (2020). Abdominal Wall Endometriosis (A Narrative Review). International Journal Of Medical Sciences, 17(4), 536.\nDonnez, J., & Dolmans, M. M. (2021). Endometriosis And Medical Therapy: From Progestogens To Progesterone Resistance To Gnrh Antagonists: A Review. Journal Of Clinical Medicine, 10(5), 1085.\nKhotimah, Q. (2024). Analisis Tata Laksana Pengobatan Kista Endometriosis. Jurnal Ners, 8(1), 558-563.\nKim, M. R., Chapron, C., Römer, T., Aguilar, A., Chalermchockcharoenkit, A., Chatterjee, S., & Yen, C. F. (2022, December). Clinical Diagnosis And Early Medical Management For Endometriosis: Consensus From Asian Expert Group. In Healthcare (Vol. 10, No. 12, P. 2515). MDPI.\nLizhen, L. I. U., Lifen, G. U. O., Chunyan, L. U. O., & Ruihong, P. E. N. G. (2025). Comparison Of Postoperative Efficacy Between Leuprorelin And Mifepristone In The Treatment Of Endometriosis. China Pharmacy, 36(11), 1379-1383.\nMaharani, C. R., Yeni, C. M., & Sinaga, J. L. (2021). Pemilihan Terapi Konservatif Dan Operatif Pada Endometriosis. Jurnal Kedokteran Syiah Kuala, 21(1), 64-73.\nMasereka, R., Kiyaka, S. M., & Sikakulya, F. K. (2022). Endometriosis Arising In A Cesarean Section Scar: A Case Report. International Journal Of Surgery Case Reports, 92, 106862.\nMirfendereski, A., & Abadian, K. (2022). A Case Report Of A Larg Rectus Muscle Size Endometriosis. Journal Of Obstetrics, Gynecology And Cancer Research, 3(4), 177-180.\nOsuga, Y., Seki, Y., Tanimoto, M., Kusumoto, T., Kudou, K., & Terakawa, N. (2021). Relugolix, An Oral Gonadotropin-Releasing Hormone Receptor Antagonist, Reduces Endometriosis-Associated Pain In A Dose–Response Manner: A Randomized, Double-Blind, Placebo-Controlled Study. Fertility And Sterility, 115(2), 397-405.\nOthman, E. R., Al-Hendy, A., Mostafa, R., Lambalk, C. B., & Mijatovic, V. (2024). Oral Gnrh Antagonists In Combination With Estradiol And Norethindrone Acetate For Pain Relief Associated With Endometriosis: A Review Of Evidence Of A Novel Class Of Hormonal Agents. International Journal Of Women's Health, 309-321.\nPaoletti, A. M., Neri, M., Pilloni, M., Marotto, M. F., Giancane, E., Vallerino, V., & Melis, G. B. (2025). Pharmacokinetic Considerations For Gonadotropin-Releasing Hormone Agonists And Antagonists To Treat Endometriosis. Expert Opinion On Drug Metabolism & Toxicology, 21(6), 649-663.\nSimanungkalit, H. M. (2016). Pengaruh Pemberian Genistein Dan Leuprolide Acetat Terhadap Ekspresi Re-Α Dan Re-Β Pada Mencit Model Endometriosis (Doctoral Dissertation, Universitas Brawijaya).\nSurrey, E. S. (2023). Gnrh Agonists In The Treatment Of Symptomatic Endometriosis: A Review. F&S Reports, 4(2), 40-45.\nSuwartono, H., Kaput, J. A., Astijani, N. M., & Saranga, D. (2022). Endometriosis Subkutan: Laporan Kasus Subcutaneous Endometriosis: Case Report. Jurnal Medical Profession (Medpro), 4(1), 29-35.\nThiel, P. S., Donders, F., Kobylianskii, A., Maheux-Lacroix, S., Matelski, J., Walsh, C., & Murji, A. (2024). The Effect Of Hormonal Treatment On Ovarian Endometriomas: A Systematic Review And Meta-Analysis. Journal Of Minimally Invasive Gynecology, 31(4), 273-279.\nWang, J. Y., Zhang, Y., & Ding, J. (2025). Oral Gonadotropin-Releasing Hormone Antagonists In The Treatment Of Endometriosis: Advances In Research. Journal Of Clinical Medicine Research, 299-308.\nYu, L., Sun, Y., & Fang, Q. (2022). Efficacy Of Laparoscopic Surgery Combined With Leuprorelin In The Treatment Of Endometriosis Associated With Infertility And Analysis Of Influencing Factors For Recurrence. Frontiers In Surgery, 9, 873698.\nZhang, S., Wang, L., Zhang, J., An, W., & Jia, L. (2021). The Efficacy And Safety Of Kuntai Capsule Combined With Leuprorelin Acetate In The Treatment Of Endometriosis: A Protocol For Systematic Review And Meta-Analysis. Medicine, 100(11), E25080.\nDownloads\nPublished\nIssue\nSection\nLicense\nCopyright (c) 2025 Amirudin Amirudin, Sanoko Tjandra\nThis work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.","source_license":"CC0","license_restricted":false}